Clinical Trials Browser

NCT02506153 2026-03-18

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,301 enrolled 16 charts

Dermatologic

Melanoma

NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Phase 3 Active not recruiting

1,150 enrolled 6 charts

Dermatologic

Melanoma

NCT04093323 2026-02-25

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Phase 2 Terminated

1 enrolled

Dermatologic

Melanoma

NCT01274338 2026-02-18

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,673 enrolled 19 charts

Dermatologic

Melanoma

NCT00539591 2025-12-23

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Phase 2 Active not recruiting

29 enrolled 28 charts

Dermatologic

Melanoma

NCT00679289 2022-10-12

Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma

Phase 2 Completed

36 enrolled 14 charts

Dermatologic

Melanoma

NCT02323659 2022-01-13

Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas

Phase 4 Terminated

100 enrolled

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT00398450 2021-03-03

Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma

Phase 1 Completed

12 enrolled

Dermatologic

Melanoma

NCT02339324 2021-02-24

Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b

Phase 1 Completed

31 enrolled

Dermatologic

Melanoma

NCT00505635 2020-09-24

Biochemotherapy With Temozolomide for Metastatic Melanoma

Phase 2 Terminated

5 enrolled 5 charts

Dermatologic

Melanoma

NCT00498979 2020-07-24

Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers

Phase 1 Completed

22 enrolled

CNSDermatologicSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Melanoma, Oligodendroglioma, Glioma, Subependymal, Gliosarcoma

NCT03552549 2019-07-24

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

Phase 2/3 Terminated

126 enrolled 9 charts

Dermatologic

Melanoma

NCT01603212 2019-05-21

Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor

Phase 1 Completed

6 enrolled

Dermatologic

Melanoma

NCT01100528 2019-02-26

Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Phase 2 Completed

38 enrolled 10 charts

Dermatologic

Uveal Melanoma

NCT00629200 2018-11-15

Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies

Phase 1 Completed

33 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT03435302 2018-02-19

HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma

Phase 3 Unknown

204 enrolled

Dermatologic

Melanoma

NCT00311558 2018-01-26

Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma

Phase 1 Terminated

18 enrolled

DermatologicSarcoma

Melanoma, Neoplasms, Sarcoma

NCT01622933 2017-08-31

Multiple Antigen-Engineered DC Vaccine for Melanoma

Phase 1 Completed

35 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis, Recurrence

NCT01409174 2017-05-31

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

Phase 1 Terminated

19 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis

NCT00613509 2016-04-14

Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma

Phase 2 Terminated

23 enrolled 14 charts

Dermatologic

Melanoma, Neoplasms

NCT00749684 2015-10-19

Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)

Completed

138 enrolled 6 charts

Dermatologic

Melanoma

NCT00723710 2015-08-26

Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)

Completed

299 enrolled 5 charts

Dermatologic

Melanoma

NCT02074605 2014-02-28

Cognitive Effects of Interferon in Patients With Melanoma

Completed

36 enrolled

Dermatologic

Melanoma

NCT01743157 2013-08-29

BBI

Phase 1/2 Completed

24 enrolled

Dermatologic

Melanoma

NCT00026143 2013-06-05

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Phase 2 Completed

60 enrolled

Dermatologic

Melanoma

NCT00217542 2013-05-03

Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery

Phase 1 Completed

42 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT01782508 2013-02-04

A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma

Phase 2 Unknown

40 enrolled

Dermatologic

Melanoma

NCT00970996 2013-01-03

BCAA

Phase 1 Completed

10 enrolled

Dermatologic

Melanoma

NCT01409187 2012-01-26

IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma

Phase 1/2 Withdrawn

Dermatologic

Melanoma

NCT00221702 2010-10-13

EADO

Phase 3 Completed

898 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis, Drug-Related Side Effects and Adverse Reactions

NCT00963664 2009-09-09

Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma

Phase 2 Withdrawn

250 enrolled

Dermatologic

Melanoma

NCT00226408 2006-06-21

Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon

Phase 3 Unknown

600 enrolled

Dermatologic

Melanoma